HEMATOPOIESIS AND STEM CELLS

GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells

*Shuyang Yu, 1 *Kairong Cui, 2 *Raja Jothi, 3 Dong-Mei Zhao, 1,4 Xuefang Jing, 1 Keji Zhao, 2 and Hai-Hui Xue 1,5

1Department of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, IA; 2Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health (NIH), Bethesda, MD; 3Biostatistics Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC; and 4Department of Internal Medicine, 5Interdisciplinary Immunology Graduate Program, Carver College of Medicine, University of Iowa, Iowa City, IA

Maintaining a steady pool of self-renewing hematopoietic stem cells (HSCs) is critical for sustained production of multiple blood lineages. Many transcription factors and molecules involved in chromatin and epigenetic modifications have been found to be critical for HSC self-renewal and differentiation; however, their interplay is less understood. The transcription factor GA binding protein (GABP), consisting of DNA-binding subunit GABP α and transactivating subunit GABP β, is essential for lymphopoiesis as shown in our previous studies. Here we demonstrate cell-intrinsic, absolute dependence on GABP α for maintenance and differentiation of hematopoietic stem/progenitor cells. Through genome-wide mapping of GABP α binding and transcriptomic analysis of GABP α-deficient HSCs, we identified Zfx and Etv6 transcription factors and prosurvival Bcl-2 family members including Bcl-2, Bcl-XL, and Mcl-1 as direct GABP target genes, underlying its pivotal role in HSC survival. GABP also directly regulates Foxo3 and Pten and hence sustains HSC quiescence. Furthermore, GABP activates transcription of DNA methyltransferases and histone acetylases including p300, contributing to regulation of HSC self-renewal and differentiation. These systematic analyses revealed a GABP-controlled gene regulatory module that programs multiple aspects of HSC biology. Our studies thus constitute a critical first step in decoding how transcription factors are orchestrated to regulate maintenance and multipotency of HSCs. (Blood. 2011; 117(7):2166-2178)

Introduction

Multilineage hematopoiesis is maintained by a pool of hematopoietic stem cells (HSCs). To sustain the production of blood cells throughout the lifetime of an individual, HSCs are capable of self-renewal to maintain the HSC pool and have the ability for multilineage differentiation.1,2 Self-renewal relies on a balance between quiescence and cell-cycle progression and a balance between survival and cell death. Recent studies have revealed that these critical processes are under the regulation of a number of transcription factors.3 For example, Gfi-1 and Foxo proteins restrain HSCs from excessive cycling,1,4 and Zfx and Tef/Etv6 are critical in suppressing HSC apoptosis,5,6 Gata2, Fli-1, and Scl/Tal1 act cooperatively in specification of hematopoiesis during embryonic development.9 Epigenetic integrity has been demonstrated to be critical for normal HSC activities as well. DNA methyltransferase 1 (Dnmt1)–mediated methyltransfer maintenance10,11 and Dnmt3a/3b-mediated de novo DNA methylation12 are all required for HSC self-renewal. Proteins with histone acetyltransferase activity such as CBP and p300 coactivators were shown to have distinct roles in regulating HSC self-renewal and differentiation.13 The Brg1 ATPase catalytic subunit in the SWI/SNF-related chromatin-remodeling complex was found to be essential for primitive erythropoiesis during embryogenesis.14 Despite increasing numbers of key players that have been identified, their interplay has not been extensively addressed in HSCs.

A functional GA binding protein (GABP) complex is a heterodimer of GABP α and GABP β subunits. GABP α is one of the Ets family transcription factors and contains a conserved Ets domain responsible for DNA binding. GABP β is unrelated to Ets factors but heterodimerizes with GABP α and possesses transactivation activity. The GABP complex has been demonstrated to have versatile roles in maintaining basic cellular functions, such as cellular respiration in mitochondria and cell-cycle progression.15 As a result, targeting GABP α in the germline resulted in early embryonic lethality.16,17 Cell type–specific roles of GABP are also well documented. In lymphocytes, we showed previously that GABP critically regulates Pax5 in developing B cells,18 interleukin-7 receptor α chain, and genes involved in T-cell receptor rearrangements in thymocytes.16,19 In this study, we investigated the roles of GABP in HSCs via tissue-specific disruption of GABP α. Recent technological advances in chromatin immunoprecipitation coupled by high-throughput parallel sequencing (ChIP-Seq) allowed genome-wide mapping of transcription factor binding locations.20 Application of this technique in hematopoietic cells, such as ChIP-Seq of GATA1 in erythroleukemia cells21,22 and PU.1 in primary B cells and macrophages,23 has offered comprehensive insights into how these transcription factors operate. Here we report genome-wide chromatin occupancy of GABP α. By combining genetic and bioinformatic approaches with functional assays, our systematic analyses revealed a GABP-controlled gene regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells.
Methods

Mice and pIpC treatment

Generation of GABP<br/>&<br/>H9251<br/>&<br/>FL/<br/>&<br/>H11001<br/>&<br/>and GABP<br/>H9251/H11001<br/>H11002<br/>using 129S6/SvEvTac embryonic stem cells was described previously.24 Mx1Cre transgenic, B6.SJL, and 129/SvEv mice were from The Jackson Laboratory. Mx1Cre-GABP<br/>H9251<br/>FL/<br/>H11001<br/>and Mx1Cre-GABP<br/>H9251<br/>FL/<br/>H11002<br/>mice and surface-stained. Percentages of LSKs and c-Kit<sup>+</sup> myeloid progenitors in Lin<sup>+</sup> BM cells are shown. (C) Total BM cellularity, LSK frequency and numbers. LSK frequency was expressed as percentages of BM nucleated cells. Absolute counts of total BM cells and LSKs were obtained from 2 tibias and 2 femurs in each mouse. (D) Numbers of myeloid progenitors, granulocytes, and developing B cells in the BM. BM cells were isolated from Mx1Cre-GABP<sup>FL2</sup> or control mice during 6-12 days after pIpC treatment, and stained for Lin<sup>+</sup>c-Kit<sup>+</sup> myeloid progenitors, Gr.1<sup>+</sup>, and B220<sup>+</sup> cells. The absolute counts were from 2 hind limbs as in panel C. (E) Analysis of LT-HSC, ST-HSC, and MPP subsets in LSKs. LSK cells were fractionated based on CD34 and Flt3 expression, and the percentage of each subset was shown in the flow cytometric profile (left panel). Absolute count of each subset was shown in the right panel. All flow cytometric data are representative of at least 3 independent experiments with similar results, and bar graphs are means ± standard deviation (SD) of pooled results (n ≥ 6). Statistical significance was calculated using the Student’s t-test, with P values shown in each relevant panel.

Flow cytometry and cellularity

Freshly dissected femurs and tibias were flushed with phosphate-buffered saline containing 2.5% fetal bovine serum, and red blood cells were lysed with ammonium chloride–potassium bicarbonate lysis buffer. For identification of Lin<sup>−</sup>Sca-1<sup>−</sup>c-Kit<sup>+</sup> cells (LSKs) and long-term HSCs (LT-HSCs), lineage markers (CD4, CD8, B220, CD11c, Gr-1, TER119, NK1.1, and Mac1), Sca-1, c-Kit, Flt3, and CD34, directly conjugated or biotinylated, were used for cell-surface staining (eBioscience or BD Biosciences), and stained cells were analyzed on FACSCalibur or Becton Dickinson LSR II (BD Biosciences). For analysis of bone marrow (BM) chimeras, CD45.1 and CD45.2 antibodies were included to discriminate sources of donor and host cells. Apoptotic state of LSKs was measured using annexin V–PE Apoptosis Detection Kit (BD Biosciences). All the data were analyzed using FlowJo software Version 8.8 (TreeStar Inc). The numbers of LSKs, LT-HSCs, short-term HSCs (ST-HSCs), and multipotent progenitors (MPPs) were calculated from the bone marrow cellularity of femurs and tibias with flow cytometry–detected frequency of each subset.

Antibody conjugation and intracellular staining

Antibodies against GABPα (H-180), Pten (C-20), Brm (N-19), and Brg1 (P-18), along with normal rabbit or goat IgG without carrier proteins, were special ordered from Santa Cruz Biotechnology. The antibodies were labeled with a fluorochrome using the Alexa Fluor 647 monoclonal antibody labeling kit (Invitrogen). Bone marrow cells from pIpC-treated Mx1Cre-GABP<sup>FL2</sup> and Mx1Cre-GABP<sup>FL2</sup> mice were surface stained, then fixed and permeabilized using Cytofix/Cytoperm solutions.

Figure 1. GABP<sub>α</sub> is required for maintaining an HSC and progenitor pool. (A) Induction of GABP<sub>α</sub>-floxed allele and experimental timeline. Mx1Cre-GABP<sub>α</sub><sup>FL2</sup> and Mx1Cre-GABP<sub>α</sub><sup>FL2</sup> mice at 5 weeks old were injected intraperitoneally with 25 μg/g body weight of pIpC as indicated. The last day of injection was designated day 0 and BM cells were harvested on indicated days for analysis. (B) Flow cytometric analysis of LSKs and c-Kit<sup>+</sup> myeloid progenitors in line-age-negative BM cells. BM cells were isolated on indicated days from pIpC-treated Mx1Cre-GABP<sub>α</sub><sup>FL2</sup> or Mx1Cre-GABP<sub>α</sub><sup>FL2</sup> mice and surface-stained. Percentages of LSKs and c-Kit<sup>+</sup> myeloid progenitors in Lin<sup>+</sup> BM cells are shown. (C) Total BM cellularity, LSK frequency and numbers. LSK frequency was expressed as percentages of BM nucleated cells. Absolute counts of total BM cells and LSKs were obtained from 2 tibias and 2 femurs in each mouse. (D) Numbers of myeloid progenitors, granulocytes, and developing B cells in the BM. BM cells were isolated from Mx1Cre-GABP<sub>α</sub><sup>FL2</sup> or control mice during 6-12 days after pIpC treatment, and stained for Lin<sup>−</sup>c-Kit<sup>+</sup> myeloid progenitors, Gr.1<sup>+</sup>, and B220<sup>+</sup> cells. The absolute counts were from 2 hind limbs as in panel C. (E) Analysis of LT-HSC, ST-HSC, and MPP subsets in LSKs. LSK cells were fractionated based on CD34 and Flt3 expression, and the percentage of each subset was shown in the flow cytometric profile (left panel). Absolute count of each subset was shown in the right panel. All flow cytometric data are representative of at least 3 independent experiments with similar results, and bar graphs are means ± standard deviation (SD) of pooled results (n ≥ 6). Statistical significance was calculated using the Student’s t-test, with P values shown in each relevant panel.
Generation of BM chimeras and CFU-Spleen<sub>12</sub>

To generate BM chimeras of Mx1Cre-GABP<sub>α</sub>/H9251<sub>2</sub> or Mx1Cre-GABP<sub>β</sub>/H9251<sub>2</sub>, donor BM cells were stained and analyzed by flow cytometry to determine LSK frequency. BM cells containing 3000 LSKs, alone or in the presence of equivalent numbers of LSKs from B6.SJL mice as protectors/competitors, were intravenously injected into F1 progeny of B6.SJL and 129/SvEv breeding that received 1050 rad whole-body irradiation at least 4 hours before injection. Five weeks later, peripheral blood was sampled and contribution from donor BM cells (CD45.2<sup>+</sup>CD45.1<sup>−</sup>) was determined before plpC treatment. For the colony-formation units in the spleen on day 12 (CFU-Spleen<sub>12</sub>) assay, Mx1Cre-GABP<sub>α</sub>/H9251<sub>2</sub> and Mx1Cre-GABP<sub>β</sub>/H9251<sub>2</sub> mice were treated with plpC, and on day 9 after last injection, 1 × 10<sup>5</sup> BM cells were injected into 900 rad–irradiated F1 recipients as described. After another 12 days, spleens from the hosts were harvested and macro-colonies were counted under a dissecting microscope.

Colony-formation assay using methylcellobiose

Whole bone marrow cells were harvested from Mx1Cre-GABP<sub>α</sub>/H9251<sub>2</sub> and Mx1Cre-GABP<sub>β</sub>/H9251<sub>2</sub> mice on day 4 after the last plpC treatment. A total of 2 × 10<sup>5</sup> BM cells were mixed with Methocult M3434 (StemCell Technologies) and plated. Ten days after culture, colony numbers of GEMM (granulocyte, erythroid, macrophage, megakaryocyte), GM (granulocyte macrophage), G (granulocyte), M (macrophage), and BFU-E (burst-forming erythroid-unit) were counted based on their distinct morphology.

Peripheral blood analysis

Peripheral blood was collected from Mx1Cre-GABP<sub>α</sub>/H9251<sub>2</sub> and Mx1Cre-GABP<sub>β</sub>/H9251<sub>2</sub> mice on various days after plpC treatment and analyzed on the Sysmex XT 2000iv automatic hematology analyzer, which is provided on loan to Dr John Widness’ laboratory (University of Iowa) from Sysmex Corporation.

BrdU uptake

To determine the proliferation rate of myeloid progenitors and LSK cells, Mx1Cre-GABP<sub>α</sub>/H9251<sub>2</sub> and Mx1Cre-GABP<sub>β</sub>/H9251<sub>2</sub> mice that have been treated with plpC were given one dose of intraperitoneal 5<sup>′</sup>-bromo-2<sup>′</sup>-deoxyuridine (BrDU) injection (1 mg). Eighteen hours later, BM cells were isolated and surface-stained, followed by fixation and permeabilization procedures as recommended in the BrdU Flow Kit (BD Biosciences).

ChIP-Seq and data analysis

Mobilized CD34<sup>+</sup> “CD133<sup>+</sup>” human hematopoietic progenitor cells (HPCs) were purified from peripheral blood lymphocytes of healthy donors using established protocols. The chromatin fragments were prepared and immunoprecipitated with an anti-GABPα antibody (H180; Santa Cruz Biotechnology) or a control IgG as described previously. The chromatin immunoprecipitation (ChIP) samples were amplified and sequenced using the Solexa 1G Genome Analyzer (Illumina). The resulting 25-bp sequence reads were mapped to the human genome (build hg18) using the Solexa Analysis Pipeline, and only reads that were mapped to unique genomic locations, with mismatches in at most 2 positions, were retained for further analysis. This yielded 4.43 million reads for the GABPα sample and 4.48 million reads for the control IgG sample.

For binding site identification, mapped GABPα reads were processed using the Site Identification from Short Sequence Reads (SISsRRs) peak finding tool. The control IgG reads as a control (see http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/sisrr/SISsRRs-Manual.pdf for details). SISsRRs 1.4 was run with option “-a” (which retains one read per genomic position even if multiple reads were mapped to that position, and thus avoids overrepresentation of one position because of polymerase chain reaction [PCR] amplification–generated bias), fragment length F set to 200, P value set to .01, and the remaining parameters set to their default values. Each identified binding site is associated with a fold-enrichment score, which is the ratio of the normalized number of GABPα sequence tags supporting the inferred binding site to the normalized number of control IgG tags supporting the exact same site. Genome-wide distribution of GABPα binding sites was determined with reference to RefSeq genes downloaded from the University of California Santa Cruz genome browser. For Motif analysis, MEME with default parameters was used to identify the consensus binding sequence with identified GABPα binding locations. The ChIP-Seq data have been deposited at the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus under accession number GSE24933.

Validation of direct GABP binding in murine hematopoietic progenitor cells by ChIP

Whole BM cells from C57BL/6 mice were subjected to lineage depletion using biotinylated lineage antibodies coupled with Dynabeads M280 Streptavidin (Invitrogen). The Lin<sup>−</sup> cells were stained for cell-surface c-Kit, and c-Kit<sup>−</sup>Lin<sup>−</sup> BM cells were isolated by either positive selection using CD117 MicroBeads (Miltenyi Biotec) or cell sorting. The chromatin fragments were prepared from Lin<sup>−</sup> or c-Kit<sup>−</sup>Lin<sup>−</sup> BM cells and immunoprecipitated with an anti-GABPα antibody or a control IgG as described previously. The enrichment of GABP binding in these murine hematopoietic progenitor cells was assessed by quantitative PCR on ABI 7300 Real Time PCR System (Applied Biosystems). For primer design in a select gene, a cross-species conserved region corresponding to a GABP binding peak based on ChIP-Seq was first identified in the human genome, and the corresponding conserved sequence in the mouse genome was used for quantitative assessment. Each primer set was tested for linear amplification range with input DNA using SYBR Advantage qPCR premix (Clontech). The Rq2 promoter with no GABP binding on ChIP-Seq was used as a negative control. For calculation of enrichment of each selected gene/region, 2<sup>−ΔΔCt</sup> was used, where ΔΔCt is the difference of Ct (crossover threshold) values detected in GABPα antibody- and IgG-precipitated samples. Primer sequences for amplification of each select gene segment are listed in supplemental Table 1A (available on the Blood Web site; see the Supplemental Materials link at the top of the online article).

Microarray and quantitative PCR

Four days after plpC treatment, whole BM cells from Mx1Cre-GABP<sub>α</sub>/H9251<sub>2</sub> and Mx1Cre-GABP<sub>β</sub>/H9251<sub>2</sub> mice were isolated and lineage-depleted, and the FL3<sup>−</sup> LSK cells were sorted directly into Trizol LS reagent (Invitrogen). After chloroform extraction, the aqueous phase was mixed with 2 volumes of ethanol and loaded onto a purification column in RNeasy Mini Kit (QIAGEN) for further purification. RNA quality was assessed using the Agilent Model 2100 Bioanalyzer. Total RNAs from 2 wild-type (WT) and 2 GABPα-deficient samples were amplified using the NuGEN WT-Ovation Pico RNA Amplification System (NuGEN). The resulting cDNA probes were hybridized to the GeneChip Mouse GENE 1.0 ST arrays (Affymetrix), scanned with the Affymetrix Model 7G upgraded scanner, and the data were collected using the GeneChip Operating Software. The data were imported into Partek Genomics Suite using Robust Multi-Chip Average normalization. Differential expression and its statistical significance were calculated using linear contrasts with an ANOVA (analysis of variance) model. All microarray data have been deposited at the NCBI Gene Expression Omnibus under accession number GSE23341.

For validation of select gene-expression changes, total RNA was amplified from GABPα-deficient and control Flt3<sup>−</sup>LSK cells as described and analyzed using quantitative PCR. Relative expression levels of select genes were normalized to that of a housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (Gapdh). Primer sequences for each transcript are listed in supplemental Table 1B.

Bioinformatic analysis with GSEA and DAVID

Gene set enrichment analysis (GSEA) software was downloaded and used for analysis according to the instructions. The normalized gene-expression profiles of GABPα-deficient Flt3<sup>−</sup>LSK cells were used as the ranked dataset. The gene sets used in enrichment assessments include (BD Biosciences), followed by intracellular staining with self-labeling antibodies or prelabeled Bc1-2 and control antibodies (BD Biosciences).

Microarray data have been deposited at the NCBI Gene Expression Omnibus under accession number GSE24933.
Results

Ablation of GABPα drastically diminished the HSC and progenitor pool

Targeting GABPα in the germline resulted in early embryonic lethality. To avoid this, GABPα was conditionally targeted by inserting LoxP sites in the Gabpa gene locus to flank exons encoding the DNA binding Ets domain, yielding a Gabpa floxed allele (GABPαFL/+.24 Crossing GABPαFL/+ mice to an EIIa transgene resulted in conversion of the GABPα-flxed allele to a GABPα-deleted allele in the germline (GABPα+/−). To investigate the functional requirements of GABP in HSCs, we used the Mx1Cre transgene to induce specific inactivation of the GABPα-floxed allele in BM cells through pIpC treatment (Figure 1A). Six Mx1Cre transgene to induce specific inactivation of the Gabpa allele in the germline (GABPαFL/H9251 transgene resulted in conversion of the GABPα encoding the DNA binding Ets domain, yielding a

12 days, spleens from the hosts were harvested and macro-colonies were counted. Shown are representative from 2 independent experiments with similar results (n = 8 animals analyzed. The colony numbers are averages of triplicate measurements of each individual mouse. (C) Ablation of GABPα diminishes CFU-Spleen colonies. Mx1Cre-GABPαFL/− and Mx1Cre-GABPαFL+/− mice were treated with pIpC, and on day 9 after last injection, 1 × 10⁶ BM cells were injected into 900 rad-irradiated hosts. After another 12 days, spleens from the hosts were harvested and macro-colonies were counted. Shown are representative from 2 independent experiments with similar results (n = 4 in each experiment). (D) Detection of apoptotic cells in LSK and myeloid progenitor subsets. Total BM cells were isolated from Mx1Cre-GABPαFL/− mice 2-4 days after pIpC treatment, lineage-depleted, and surface-stained with c-Kit and Sca-1, followed by staining with annexin V and 7-AAD. The percentage of annexin V−7-AAD− cells in each subset is shown. (E) Enhanced cell death of GABPα-deleted LSKs and myeloid progenitors. Data were pooled results from 2 independent experiments with 6 mice of each genotype analyzed.

C2-curated gene sets from the Broad Institute and the GABP-bound gene set. The latter contained enriched GABP binding within 2 kb of the transcription initiation sites (TISs) in 7782 genes and was constructed in-house based on ChIP-Seq results using human HPCs. For functional annotation of GABP-activated or -repressed direct target genes, the extracted gene list was uploaded onto the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources (http://david.abcc.ncifcrf.gov) and analyzed following reported protocols.29

In summary, we show that GABPα in the HSC progenitor pool is required for HSC differentiation and survival.

Figure 2. GABPα is required for HSC differentiation and survival. (A) Peripheral blood analysis. Blood was collected from Mx1Cre-GABPαFL/− and Mx1Cre-GABPαFL+/− mice on indicated days after pIpC treatments and analyzed on Sysmex XT 2000i automatic hematology analyzer. Numbers of platelets and white blood cells (WBCs) are shown, with horizontal bars denoting mean values in each group. Data are pooled results from 2-3 independent experiments with 5-13 animals analyzed. (B) Colony formation assays using methylcellulose. Total BM cells from Mx1Cre-GABPαFL/− and Mx1Cre-GABPαFL+/− mice were isolated 4 days after the last pIpC injection. A total of 2 × 10⁴ BM cells were mixed and plated with M3434 methylcellulose-based media. Colonies of each type were counted after 10-day culture. GEMM indicates granulocyte, erythroid, macrophage, megakaryocyte; GM, granulocyte macrophage; G, granulocyte; M, macrophage; BFU-E, burst-forming unit-erythroid. Data are representative from 2 independent experiments with similar results shown. (C) Detection of apoptotic cells in LSK and myeloid progenitor subsets. Total BM cells were isolated from Mx1Cre-GABPαFL/− and Mx1Cre-GABPαFL+/− mice 2-4 days after pIpC treatment, lineage-depleted, and surface-stained with c-Kit and Sca-1, followed by staining with annexin V and 7-AAD. The percentage of annexin V−7-AAD− cells in each subset is shown. (D) Enhanced cell death of GABPα-deleted LSKs and myeloid progenitors. Data were pooled results from 2 independent experiments with 6 mice of each genotype analyzed.

Figure 2. GABPα controls HSC maintenance and differentiation.2169BLOOD, 17 FEBRUARY 2011 • VOLUME 117, NUMBER 7

References

1. Ablation of GABPα drastically diminished the HSC and progenitor pool.

2. Targeting of GABPα in the germline resulted in early embryonic lethality.16,17 To avoid this, GABPα was conditionally targeted by inserting LoxP sites in the Gabpa gene locus to flank exons encoding the DNA binding Ets domain, yielding a Gabpa floxed allele (GABPαFL/+.24 Crossing GABPαFL/+ mice to an EIIa transgene resulted in conversion of the GABPα-flxed allele to a GABPα-deleted allele in the germline (GABPα+/−).24 To investigate the functional requirements of GABP in HSCs, we used the Mx1Cre transgene to induce specific inactivation of the Gabpa-floxed allele in BM cells through pIpC treatment (Figure 1A). Six to 12 days after the last pIpC treatment, the total BM cells in Mx1Cre-GABPαFL/− mice were reduced to approximately one-third of those in Mx1Cre-GABPαFL+/− controls (Figure 1C). Both lineage-negative, Sca1−, and c-Kit−high (LSK) subset containing HSCs and lineage-negative, Sca1−, and c-Kit−high myeloid progenitors were greatly diminished in frequency and absolute numbers in Mx1Cre-GABPαFL/− mice (Figure 1B-D). Granulocytes and developing B cells in the BM were also significantly decreased (Figure 1D), indicating an acute failure on induced disruption of GABPα.

3. LSK cells are heterogeneous and consist of LT-HSCs, short-term HSCs (ST-HSCs), and MPPs, and these subsets can be distinguished by CD34 and Flt3 expression.30 On day 6 after pIpC treatments when LSKs were still reliably detectable, whereas all 3 subsets were greatly diminished in absolute numbers, the CD34−Flt3+ MPPs were more drastically decreased (Figure 1E). Flt3 marks differentiation of HSCs to more committed progenitors,30 and direct binding of GABPα to the Flt3 locus was found in human hematopoietic progenitor cells (HPCs) based on ChIP-Seq data (detailed in supplemental Table 3). The selective disappearance of Flt3-expressing MPPs is thus likely a result of direct regulation of Flt3 by GABP and represents an HSC differentiation defect because of GABPα deficiency. These observations collectively suggest that ablation of GABPα impairs HSC maintenance as well as further differentiation.
GABPα was intrinsically required for HSC activity and survival

We next determined the impact of GABPα inactivation on HSC differentiation. In peripheral blood, severely diminished platelets and greatly reduced white blood cells were observed in the pIpC-treated Mx1Cre-GABPαFL/− mice (Figure 2A). Using BM cells from pIpC-treated Mx1Cre-GABPαFL/− and control mice in an in vitro methylcellulose colony formation assay, we found substantial and consistently reduced numbers of all different types of colonies as a result of GABPα ablation (Figure 2B). By an in vivo assay of colony-forming units in the spleen on day 12 (CFU-Spleen12), whereas expected numbers of macro-colonies were found in the host spleens when control BM cells were transferred, almost no colonies formed in mice received Mx1Cre-GABPαFL/− BM cells (Figure 2C). These findings indicate that GABPα deletion eliminated HSC activity and resulted in failure to sustain various blood lineages. We next explored the fate of HSCs on induced deletion of GABPα by measuring cell apoptosis. Using annexin-V and 7-AAD staining, both LSKs and Lin−c-Kit+ myeloid progenitors in Mx1Cre-GABPαFL/− mice exhibited greatly increased apoptosis, with LSKs showing more exacerbated cell death (Figure 2D-E). These GABPα deficiency-derived defects are reminiscent of HSCs and progenitors lacking Etv6, or both c-Myc and N-Myc, or both Lyl1 and Scl,8,31,32 indicating the absolute dependence of HSCs and progenitors on GABPα for survival.

Mx1Cre activity can be induced by pIpC treatment in both nucleated BM cells and other cells in the bones constituting HSC niches. To determine whether the defects in HSC maintenance because of GABPα deficiency are cell intrinsic, we transferred BM cells from Mx1Cre-GABPαFL/− or Mx1Cre-GABPαFL/− mice to irradiated F1 progeny of B6.SJL and 129/SvEv breeding and established BM chimeras (Figure 3A). Treatment with pIpC eliminated GABPαFL/−-derived LSKs but not those from GABPαFL+/+ mice (Figure 3B). To further demonstrate the relative maintenance of GABPα-deficient LSKs, we transferred Mx1Cre-GABPαFL/− or Mx1Cre-GABPαFL/− along with B6.SJL BM cells as competitors into irradiated F1 progeny (Figure 3C), and then treated the mixed BM chimeras with pIpC. Whereas the test cell–to–competitor cell ratio was not affected in mice transferred with GABPαFL+/+ BM cells after pIpC treatment, GABPαFL/−-derived LSKs were diminished and hence the test to competitor ratio was greatly reduced (Figure 3D). These observations thus indicate that GABPα is intrinsically required for maintaining HSCs.

Genome-wide mapping of GABP binding locations in human HPCs

To investigate the molecular basis for regulation of HSC maintenance and biologic activities by GABP, we first used ChIP-Seq to map GABP binding locations across the genome in HSCs.26 Given the paucity of murine LSK cells, we used purified CD34+/CD133−c-Kit+ Thy1+ HPCs from human peripheral blood to obtain sufficient genomic DNA for ChIP.26 The sequence tags were processed using SISSRs peak finding tool27 to identify GABP binding sites genome-wide (Figure 4A). By setting of FDR < .01, a total of 17 627 binding locations were identified and distributed in the promoter, genic, and intergenic regions (Figure 4B). It is of note that more than 50% of GABP binding locations were found to be close to TTSs (within 2 kb or in 5′-UTR). This is in contrast to what was found in ChIP-Seq of GATA-1 in mouse erythroleukemia cells, where only 13% of GATA-1 binding was located within 10 kb of TTSs.21 De novo motif analysis confirmed the presence of core consensus sequence motif “(a/c)GGAA(g/a)” as the top motif present within more than 80% of the identified GABP binding sites, and further revealed “(c/g)CGAAGT” as the most preferred GABP binding sequence based on ChIP enrichment ranking (supplemental Figure 1A). The second-ranked sequence motif “GGGA(a/g)(t/a)TGTAGT” was found in approximately 10% of
the identified GABP binding sites (supplemental Figure 1B). The secondary motif may represent a site for recruitment of GABP through protein-protein interaction, or alternatively a genuine GABP binding consensus sequence, because approximately half of a set of 104 mouse DNA-binding proteins were found to recognize multiple different sequence motifs using a protein-binding microarray technology. For the primary GABP binding motif, the ChIP-Seq–predicted GABP binding locations were independently confirmed in select gene loci using in vitro electrophoretic mobility shift assays (supplemental Figure 2). Interestingly, comparative analysis with gene-expression profiles of human HPCs revealed that GABP binding was positively correlated with genes expressed at higher levels (Figure 4C). GABP has been known to mediate both transcription activation and repression; however, this observation suggests that GABP appears to be more dominantly associated with activation of gene transcription in HPCs/HSCs.

**GABP deficiency–altered transcriptome in HSCs**

To further investigate the molecular basis of GABP deficiency–derived HSC defects and functional relevance of GABP occupancy across the HPC/HSC genome, we performed whole-genome transcriptome analysis on GABP-deficient and control Flt3−LSKs (containing both LT- and ST-HSCs). By the setting of $P < .05$ for
Significantly differential expression (based on ANOVA model), 379 genes were up-regulated and 531 genes down-regulated for >1.5 fold because of GABPα deficiency. Remarkably, among the top 20 down-regulated genes were an Ets family transcription factor Fli-1 and a homeodomain protein Meis1, which have been known to be essential for definitive hematopoiesis. Detailed analysis using functional annotation tools in the DAVID bioinformatic resources revealed that the differentially regulated genes because of GABPα deficiency included transcription factors and genes involved in regulation of apoptosis, cell-cycle progression, DNA repair, and epigenetic modification including DNA methylation and histone acetylation (supplemental Table 2). Further pathway analysis using KEGG (Kyoto Encyclopedia of Genes and Genomes) and BioCarta databases revealed that disruption of GABPα perturbed several pathways that regulate HSC biology. Consistent with increased apoptosis of GABPα-deficient HSCs, we observed diminished expression of several molecules in the apoptosis pathway, including Bcl-2/Xi (Figure 5A). Wnt signaling has been implicated in promoting HSC expansion as well as maintaining HSC quiescence/self-renewal, and a number of molecules in this pathway were decreased in expression in GABPα-deficient Flt3−LSK cells (Figure 5B). On the other hand, several players in the adipocyte/skeletal signaling pathway and Rac1 cell motility signaling pathway were increased in expression because of loss of GABPα (Figure 5C-D). Bone marrow adipocytes were recently reported to negatively regulate HSC repopulation capacity, and alterations in the Rac small GTPases affected mobilization from the bone marrow. These analyses suggest that GABP has a multifaceted role in maintaining HSC homeostasis and functionality.

Systematic identification of GABP-activated and -repressed direct target genes

Using the genome-wide GABP occupancy data in human HPCs, we wished to determine which genes are direct targets of GABP. Focusing on genes that harbor GABP binding within 2 kb of their TSSs, we constructed an HSC/HPC GABP-bound gene set containing 7782 unique genes (hereafter referred to as GABP-bound genes). By direct comparison with differentially regulated genes described in the previous section, 246 of 531 down-regulated genes and 100 of 379 up-regulated genes were GABP-bound genes (Figure 5E). These genes constitute only 3.3% for down-regulated and 1.3% for up-regulated among all the GABP-bound genes. So as not to overlook other GABP direct targets that mediate regulation of HSC biologic activities, we used GSEA, which employs the Kolmogorov-Smirnov statistics to assess the degree of enrichment of a given gene set in the ranked gene-expression profiling of GABPα deficiency, independent of fold-change–based preselection/cutoff. This approach is powerful in identifying relevant genes that are associated with one particular biologic process, which may be hard to distinguish at the level of individual genes. Comparison of the GABP-bound gene set with gene-expression profiles using GSEA revealed that 2130 genes (27.4%) are at the leading edge of positively correlated genes (hereby defined as GABP-activated direct targets; Figure 6A). In contrast, only 294 genes (approximately 3.8%) were negatively correlated (defined as GABP-repressed direct targets; Figure 6A). This analysis substantially expanded GABP direct targets and made it more evident that GABP acts more dominantly as a transcriptional activator as observed in Figure 4C. Functional annotation of the expanded GABP direct target genes using DAVID was summarized in supplemental Table 3, revealing that GABP directly regulates genes involved in telomere maintenance and chromatin remodeling, in addition to functional categories in supplemental Table 2. A recent study mapping binding locations of Scl/Tal1 in a hematopoietic precursor cell line identified and validated that SCL directly regulates 16 other critical transcription factors. By stringent fold-expression change and P value cutoff, only Fli-1 and Hhex out of the 16 factors were found to be GABP direct targets. However, GSEA identified 4 additional factors including Runx1, Runx2, Myb, and Ly1 as GABP-activated genes (Figure 6B). The conventional analysis and GSEA thus provided complementary information that allows us to systematically map GABP target genes.

We next performed GSEA using C2 curated gene sets, which revealed strikingly strong positive correlation of GABP-regulated genes with those previously defined HSC-related datasets (Figure 6C top panels; supplemental Figure 3), supporting direct association of GABP with regulation of stem cell signature genes. Interestingly, among negatively correlated genes (ie, up-regulated expression because of loss of GABPα), highly enriched are gene sets with up-regulated expression in mature blood cells compared with BM or fetal liver HSCs (Figure 6D; supplemental Figure 3). This observation implies that GABP might be actively involved in repression of genes expressed in more differentiated blood cells, contributing to sustaining multipotency of HSCs.

Consistent with massive apoptosis of HSCs on loss of GABPα (Figure 2D-E), an apoptosis-related gene set (containing Bcl-2 and...
Bcl-X<sub>L</sub>) was enriched in genes positively regulated by GABPα (Figure 6E). Recent studies demonstrated critical requirements of Pten<sup>39,40</sup> p53<sup>3</sup>,<sup>41</sup> and TGF-β<sup>42</sup> pathways in restraining HSCs from hyperproliferation and thus maintaining their relative quiescence. Additionally, DNA damage repair<sup>43</sup> and telomere maintenance<sup>44</sup> are critical for maintaining HSC functionality during the process of aging. Further detailed GSEA analysis revealed that a substantial portion of genes involved in each of these pathways was positively regulated by GABP (Figure 6E; supplemental Figure 3). These analyses suggest that GABP is controlling a wide spectrum of HSC activities, including maintaining HSC quiescence, self-renewal, and multipotency, in addition to survival.

Based on analysis with GSEA and DAVID and relevance to HSC biology, we validated GABP occupancy in select gene loci in murine hematopoietic precursors and multipotent progenitors.7,8 For other genes such as Atm and Zfx that were dramatically down-regulated on induced ablation of GABPα in the TGF-β signaling pathway,46 Atm in the DNA repair pathway,<sup>43</sup> Terf2 in telomere maintenance,<sup>44</sup> Foxo3a transcription factor,<sup>5,6</sup> and Pten itself<sup>39,40</sup> in Pten signaling pathway. To further substantiate these findings, we examined protein expression of select GABP target genes by intracellular staining. Induced disruption of the *Gabpa* alleles eliminated GABPα expression in LSK cells from the Mx1Cre-GABP<sup>α</sup>−/− mice (Figure 7B). Consistent with their greatly diminished transcript levels (by approximately 10-fold or more), Bcl-2 and Pten proteins were substantially decreased in GABPα-deficient LSKs (Figure 7B). Reduction of the Bcl-2 and Pten proteins was also confirmed in myeloid progenitors from the Mx1Cre-GABPα<sup>FL−/−</sup> mice (supplemental Figure 4). For other genes such as Atm and Zfx that were dramatically down-regulated on induced ablation of GABPα but were not validated on protein levels because of lack of intracellular staining antibodies, we further validated their reduction on transcript levels using a second independent primer set (supplemental Figure 5). These observations thus lend additional support of our high-throughput approaches in identifying GABP targets in HSCs and progenitors.
Given the known role of Foxo3a and Pten in restraining HSC proliferation,5,6,39,40 one would predict that their decreased expression in GABPα-deficient HSCs may result in HSC hyperproliferation. After pulsing the mice with 5'-bromo-2'-deoxy-uridine (BrdU) for 18 hours, we indeed found increased BrdU incorporation in myeloid progenitors and more evidently in LSK cells from pIpC-treated Mx1Cre-GABPα/FL/ mice (Figure 7C-D). Thus, molecular analysis of GABP target genes is instructive in identifying a novel role of GABP in sustaining relative quiescence of HSCs in addition to their survival. It is noteworthy that hyperproliferation and apoptosis have been known to be interconnected in both biologic and pathologic conditions.47 Chromatin remodeling as well as epigenetic modifications including DNA methylation and histone acetylation are essential to multiple aspects of HSC activities. We found that GABP directly regulates the expression of Brm (encoded by Smarca4) and Brg1.
Table 1. Validation of select GABP-activated direct target genes in HSCs

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Fold enrichment on ChIP-Seq of human HPCs</th>
<th>Validation of GABP binding in Lin− BM cells (fold enrichment)</th>
<th>Validation of GABP binding in c-Kit+ Lin− BM cells (fold enrichment)</th>
<th>Validation of GABP binding in GABPα-null Flt3− LSKs (ratio of KO/WT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apoptosis regulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bcl2</td>
<td>Bcl-2 (B-cell leukemia/lymphoma 2)</td>
<td>14</td>
<td>2.6 ± 1.3†</td>
<td>3.4 ± 1.8†</td>
<td>0.06 ± 0.09†</td>
</tr>
<tr>
<td>Bcl21</td>
<td>Bcl-X1 (Bcl-2-like 1)</td>
<td>18</td>
<td>35.5 ± 15.1†</td>
<td>33.7 ± 5.9†</td>
<td>0.24 ± 0.25†</td>
</tr>
<tr>
<td>Mcl1</td>
<td>Mcl-1 (myeloid cell leukemia sequence 1)</td>
<td>6</td>
<td>6.9 ± 3.5†</td>
<td>5.8 ± 1.8</td>
<td>0.26 ± 0.09†</td>
</tr>
<tr>
<td>Transcription factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zfx</td>
<td>Zfx (zinc finger protein X-linked)</td>
<td>14</td>
<td>2.7 ± 1.0†</td>
<td>2.1 ± 0.2†</td>
<td>0.03 ± 0.04†</td>
</tr>
<tr>
<td>Etv6</td>
<td>Etv6/Tel (ets variant gene 6)</td>
<td>6</td>
<td>2.1 ± 1.0†</td>
<td>1.6 ± 1.0§</td>
<td>0.24 ± 0.11†</td>
</tr>
<tr>
<td>Smad4</td>
<td>Smad4 (MAD homolog 4)</td>
<td>14</td>
<td>1.9 ± 0.7†</td>
<td>2.2 ± 0.8†</td>
<td>0.29 ± 0.26†</td>
</tr>
<tr>
<td>Foxo3</td>
<td>Foxo3a (forkhead box O3)</td>
<td>4</td>
<td>1.8 ± 0.5†</td>
<td>2.9 ± 1.7†</td>
<td>0.27 ± 0.13†</td>
</tr>
<tr>
<td>Gabpa</td>
<td>Gabpa</td>
<td>90</td>
<td>8.2 ± 3.2†</td>
<td>39.5 ± 7.9†</td>
<td>0.09 ± 0.15†</td>
</tr>
<tr>
<td>Gabpb1</td>
<td>Gabpb1</td>
<td>32</td>
<td>2.1 ± 0.6†</td>
<td>2.1 ± 1.0†</td>
<td>0.28 ± 0.25†</td>
</tr>
<tr>
<td>DNA repair</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atm</td>
<td>ATM (ataxia telangiectasia mutated homolog)</td>
<td>43</td>
<td>5.1 ± 3.1†</td>
<td>3.5 ± 0.8†</td>
<td>The Atm transcript was not consistently detected in KO cells.</td>
</tr>
<tr>
<td>Telomere maintenance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Terf2</td>
<td>TRF2 (telomeric repeat binding factor 2)</td>
<td>20</td>
<td>8.0 ± 2.8†</td>
<td>5.2 ± 1.6†</td>
<td>0.42 ± 0.32†</td>
</tr>
<tr>
<td>Signaling molecules</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pten</td>
<td>PTEN (phosphatase and tensin homolog)</td>
<td>17</td>
<td>1.9 ± 0.6†</td>
<td>1.5 ± 0.5†</td>
<td>0.11 ± 0.11†</td>
</tr>
<tr>
<td>DNA methylation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dnmt1</td>
<td>Dnmt-1 (DNA methyltransferase 1)</td>
<td>19</td>
<td>7.4 ± 1.9†</td>
<td>4.7 ± 1.4†</td>
<td>0.54 ± 0.17†</td>
</tr>
<tr>
<td>Histone acetylation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ep300</td>
<td>p300 (E1a binding protein p300)</td>
<td>11</td>
<td>2.3 ± 0.6†</td>
<td>1.8 ± 0.2†</td>
<td>0.38 ± 0.16†</td>
</tr>
<tr>
<td>Myst4</td>
<td>MYST-4 (MYST histone acetyltransferase 4)</td>
<td>13</td>
<td>9.5 ± 3.6†</td>
<td>10.9 ± 4.4†</td>
<td>0.2 ± 0.25†</td>
</tr>
<tr>
<td>Chromatin remodeling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smarca2</td>
<td>Brm/BAF190B</td>
<td>12</td>
<td>2.3 ± 1.6§</td>
<td>1.9 ± 0.8†</td>
<td>0.05 ± 0.05†</td>
</tr>
<tr>
<td>Smarca4</td>
<td>Brm/BAF190A</td>
<td>15</td>
<td>3.5 ± 1.9†</td>
<td>2.9 ± 1.1†</td>
<td>0.38 ± 0.11†</td>
</tr>
</tbody>
</table>

KO indicates Mx1Cre-GABPαFL/− and WT, Mx1Cre-GABPαFL/+. Select genes under different functional categories were validated for GABP binding and GABP-dependent expression. The gene symbols, commonly gene names, and fold enrichment of GABP binding in human HPCs were summarized in the first 3 columns. Lin− and c-Kit+ Lin− murine BM cells from WT C57BL/6 mice were used for validation of GABP binding using quantitative PCR. Data are means ± SD of 2 independent experiments with each sample measured in duplicates or triplicates. For validation of gene-expression changes, Flt3− LSK cells were sorted from pIpC-treated Mx1Cre-GABPαFL/− and Mx1Cre-GABPαFL/− mice, cDNA amplified and quantitatively determined. Data are means ± SD of 3 independent experiments with each sample measured in duplicates. Statistical significance was determined using the Student t-test.

Note that in terms of fold enrichment, the binding of GABPα to the Etv6, Pten, Ep300, and Smarca2 gene loci was relatively weak especially in c-Kit+ Lin− murine BM cells. One possible explanation might be that the affinity of GABPα binding to these loci was low and the detection was limited by low numbers of c-Kit+ Lin− BM cells that can be obtained. Alternatively, enriched binding of GABPα might be more specific in primitive HSCs, and the binding signal was diluted by other non-HSC cells included in the c-Kit+ Lin− BM cells.

*Binding of GABPα in the Bcl2L2 locus was in intron 1, more than 2 kb from its TIS (see Figure 4A).
†P < .05.
‡P < .01.
§Not significant.
(Smarca2) subunits in SWI/SNF chromatin remodeling complex, DNA methyltransferase 1 (Dnmt1), and p300 (Ep300) and Myst4 histone acetyltransferases in HSCs. Identification of 228 high-confidence binding sites for Scl/Tal1 using a hematopoietic precursor cell line and by revealing. Wilson et al identified 228 high-confidence binding sites interplay using such global approaches seems both imperative and to be identified to critically regulate HSCs, elucidation of their factors and chromatin/epigenetic modifiers have been and continue pluripotent stem cells. As increasing numbers of transcription tendency and self-renewal of ESCs and efficient generation of induced pluripotent stem cells. Recent studies have demonstrated that HSCs respond to interferon-α stimulation, showing increased phosphorylation of STAT1 and Akt. It is thus possible that a portion of the differentially regulated genes in GABP- deficient Flt3 – LSKs may represent differences of these cells in responding to interferon-α. The global GABP occupancy data may have helped minimize this side effect, albeit not completely. In addition, the dominant impact of GABP ablation on HSC survival makes it unfeasible to experimentally demonstrate all possible functional alterations inferred from bioinformatic analyses in GABP- null HSCs. These caveats might be overcome through systematic structure-function analysis using mixed chimeric mice generated from WT blastocysts and embryonic stem cells expressing mutant GABP proteins, as has been done for the p300 coactivator. The GABPβ subunit in the complex is known to exist in multiple isoforms, including GABPβ1L and GABPβ1S (both encoded by Gabpb1 as splice variants) and GABPβ2 (encoded by Gabpb2). In contrast to early embryonic lethality caused by GABPα deficiency, mice lacking GABPβ1L or GABPβ2 were viable. We recently found that mice lacking both GABPβ1L and GABPβ2 remained viable and exhibited age-dependent loss of HSCs (S.Y. and H.-H.X., unpublished observations, October 2010). Further analyses along these lines will help dissect distinct roles of GABPα structural domains and GABPβ isoforms in regulating HSC activities.

It is of note that not all GABP-bound genes are altered in expression on GABPα inactivation and that among all the validated GABP-activated direct target genes, some including Atm, Pten, and Brm are more strictly dependent on GABPα expression whereas others are not. One plausible explanation might be that loss of GABPα was compensated, to different degrees, by other Ets family transcription factors because multiple Ets proteins such as Ets1, Elf-1, Elk-1, and GABPα can co-occupy the same cis-regulatory elements as revealed by genome-wide mapping of their binding locations. It is also proposed that a transcription factor can

**Discussion**

Through systematic genetic, bioinformatic, and functional analyses, our data reveal that GABP controls a key gene-regulatory module and has multifaceted biologic roles in HSCs (Figure 7G). The GABP-controlled module contains several layers of regulation that connect with HSC biologic activities. First, GABP directly regulates the prosurvival Bcl-2 family members that are critical for HSC survival, Flt3 for HSC differentiation, Pten for HSC quiescence, and genes involved in DNA damage repair and telomere maintenance that control HSC aging. The next level of regulation comes from direct regulation of other key transcription factors with known roles in HSC activities. These include Zifx and Etv6 that are essential for HSC survival and Foxo3a that has pivotal roles in maintaining HSC quiescence and self-renewal. Interestingly, GABPα directly binds to its own gene locus and regulates the expression of its interacting partner, GABPβ1 (Table 1), suggesting that GABP forms a positive feedback loop on its own expression through self-enforcing auto-regulation. The third regulatory effect by GABP lies in direct or indirect regulation of genes involved in chromatin remodeling and epigenetic modifications, which may globally impact HSC gene expression, including other GABP direct targets described above. Collectively, our systematic approaches elucidate the breadth of molecular events controlled by GABP in HSCs.

The genome-wide profiling of transcription factor binding locations in a given cell type has allowed an unprecedented opportunity to systematically examine global activity of this factor. Application of this powerful approach to murine embryonic stem cells (ESCs) has led to elucidation of an interactive gene-regulatory network, which facilitated molecular understanding of pluripotency and self-renewal of ESCs and efficient generation of induced pluripotent stem cells. As increasing numbers of transcription factors and chromatin/epigenetic modifiers have been and continue to be identified to critically regulate HSCs, elucidation of their interplay using such global approaches seems both imperative and revealing. Wilson et al identified 228 high-confidence binding sites for Scl/Tal1 using a hematopoietic precursor cell line and by transgenic models they validated direct regulatory connections between Scl/Tal1 and 16 other key transcription factors in hematopoiesis. Of the 228 sites/gene loci occupied by Scl/Tal1, 42 are GABP-activated and 1 is GABP-repressed, and among the 16 validated transcription factors, 6 are GABP direct targets (Figure 6B). Such comparative analysis of high-throughput data suggests that these common downstream targets may serve as an interface for crosstalk between GABP- and Scl/Tal1-controlled transcription modules. The study by Wilson et al and our study thus constitute a starting point, and a similar approach can be extended to other critical transcription factors with well-defined roles in HSCs, aiming to determine how individual modules interact with each other to form a transcriptional network in the adult stem cells.

Dissection of GABP-regulated genes provided molecular explanation of biologic defects in the GABPα-targeted animals. The direct regulation of prosurvival members of Bcl-2 family, Zifx and Tel/Etv6 transcription factors, and indirect regulation of granzyme B by GABP explain the rapidly vanishing HSC pool on loss of GABPα. Identification of Pten and Foxo3a as GABP direct targets assisted revealing a novel role of GABP in maintaining HSC quiescence. Other GABP-regulated genes, including CBP and p300 coactivators, DNA methyltransferases, Atm, and Tef2 further predict that GABP deficiency may result in impaired self-renewal during serial transplantation and/or accelerated aging. The critical requirement of GABPα for HSC survival has limited us to the use of type I interferon–mediated acute disruption of GABPα, because of the strong selection against GABPα-null cells when a constitutively expressed lineage-specific CRE recombinase was used. Recent studies have demonstrated that HSCs respond to interferon-α stimulation, showing increased phosphorylation of STAT1 and Akt. It is thus possible that a portion of the differentially regulated genes in GABPα- deficient Flt3– LSKs may represent differences of these cells in responding to interferon-α. The global GABPα occupancy data may have helped minimize this side effect, albeit not completely. In addition, the dominant impact of GABPα ablation on HSC survival makes it unfeasible to experimentally demonstrate all possible functional alterations inferred from bioinformatic analyses in GABPα-null HSCs. These caveats might be overcome through systematic structure-function analysis using mixed chimeric mice generated from WT blastocysts and embryonic stem cells expressing mutant GABPα proteins, as has been done for the p300 coactivator. The GABPβ subunit in the complex is known to exist in multiple isoforms, including GABPβ1L and GABPβ1S (both encoded by Gabpb1 as splice variants) and GABPβ2 (encoded by Gabpb2). In contrast to early embryonic lethality caused by GABPα deficiency, mice lacking GABPβ1L or GABPβ2 were viable. We recently found that mice lacking both GABPβ1L and GABPβ2 remained viable and exhibited age-dependent loss of HSCs (S.Y. and H.-H.X., unpublished observations, October 2010). Further analyses along these lines will help dissect distinct roles of GABPα structural domains and GABPβ isoforms in regulating HSC activities.

It is of note that not all GABP-bound genes are altered in expression on GABPα inactivation and that among all the validated GABP-activated direct target genes, some including Atm, Pten, and Brm are more strictly dependent on GABPα expression whereas others are not. One plausible explanation might be that loss of GABPα was compensated, to different degrees, by other Ets family transcription factors because multiple Ets proteins such as Ets1, Elf-1, Elk-1, and GABPα can co-occupy the same cis-regulatory elements as revealed by genome-wide mapping of their binding locations.
function as an individual at a subset of its binding sites and have different “community” function at other sites. The “community” roles may be mediated through interaction with other factors and/or recruitment of chromatin remodeling or histone modification molecules. As a result, a loss of a single factor may be less consequential to transcription of the nearby genes. Detailed analysis of such sites awaits accumulation of more global data on transcription factor binding and chromatin/histone modification states in the same cell type. Our studies, along with those of Wilson et al., constitute initial steps toward a comprehensive understanding of the gene-regulatory network in HSCs. Decoding how key transcription factors are wired together in HSCs will guide successful manipulation of the outcomes of HSC homeostasis and differentiation for therapeutic purposes.

Acknowledgments

We are grateful to Dr Steven Burden (Skirball Institute, NYU Medical School) for providing GABPαα-targeted mice. We thank Earl Gingerich and Robert Schmidt for kind assistance with operating the Sysmex XT 2000i vi hematology analyzer; Garry Hauser and Tom Bair (DNA Facility) for performing microarray analysis and assistance with the data analysis, respectively; Dr Hauser and Tom Bair (DNA Facility) for performing microarray analysis and assistance with the data analysis, respectively; Dr John Colgan, John Harty, Dana Levasseur, Thomas Waldschmidt, and Nicolas Zavazava for critical reading of the manuscript.

This study is supported by NIH grants AI042767 and HL095540 (H-H.X.), the intramural research program of the National Heart, Lung and Blood Institute, NIH (K.Z.), and the National Institute of Environmental Health Sciences (ZIAES 102625-01; R.J.).

Authorship

Contribution: S.Y. performed all the experiments unless indicated otherwise and analyzed the data; K.C. performed ChiP-Seq; R.J. analyzed the ChIP-Seq data; D.-M.Z. contributed to flow cytometric experiments and data analysis; X.J. contributed to EMSA experiments; K.Z. directed the ChiP-Seq analysis; H.-H.X. conceived the research, analyzed the data, and wrote the manuscript; and all authors edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for X.J. is Indiana University School of Medicine, Northwest Campus, Gary, IN.

Correspondence: Hai-Hui Xue, 51 Newton Rd, BSB 3-710, Iowa City, IA 52246; e-mail: hai-hui-xue@uiowa.edu.

References

sity and complexity in DNA recognition by tran-
scription factors. Science. 2009;324(5935):1720-
1723.
34. Fleming HE, Janzen V, Lo Celso C, et al. Wnt sig-
aling in the niche enforces hematopoietic stem 
cell quiescence and is necessary to preserve 
274-283.
35. Naveiras O, Nardi V, Wenzel PL, Hauschka PV,
Fahey F, Daley GQ. Bone- marrow adipocytes as 
negative regulators of the haematopoietic micro-
etic cell regulation by Rac1 and Rac2 guanosine 
triphosphatases. Science. 2003;302(5644):445-
449.
The transcriptional program controlled by the 
stem cell leukemia gene Scl/Tal1 during early em-
byronic hematopoietic development. Blood. 2009;
113(22):5456-5465.
38. Ivanova NB, Dimos JT, Schaniel C, Hackney JA,
Moore KA, Lemischka IR. A stem cell molecular 
39. Yilmaz OH, Valdez R, Theisen BK, et al. Pten de-
pendence distinguishes haematopoietic stem 
2006;441(7092):475-482.
40. Zhang J, Grindley JC, Yin T, et al. PTEN main-
tains hematopoietic stem cells and acts in lin-
2006;441(7092):518-522.
41. Liu Y, Elf SE, Miyata Y, et al. p53 regulates hemat-
opoietic stem cell quiescence. Cell Stem Cell. 
42. Yamazaki S, Iwama A, Takayanagi S, Eto K, 
Ema H, Nakauchi H. TGF-beta as a candidate 
bone marrow niche signal to induce hematopoi-
etic stem cell hibernation. Blood. 2009;113(6):
1250-1256.
43. Ito K, Hirao A, Arai F, et al. Regulation of oxidative 
stress by ATM is required for self-renewal of 
haematopoietic stem cells. Nature. 2004;
431(7011):997-1002.
44. Rossi DJ, Bryder D, Seita J, Nussenzweig A, 
Hoeijmakers J, Weissman IL. Deficiencies in 
DNA damage repair limit the function of haemato-
poietic stem cells. Nature. 2004;
243(7145):725-729.
45. Opferman JT, Letai A, Beard C, Sorcinelli MD,
Ong CC, Korsmeyer SJ. Development and main-
tenance of B and T lymphocytes requires anti-
apoptotic MCL-1. Nature. 2003;426(6967):671-
676.
critical for self-renewal of hematopoietic stem 
47. Hipfner DR, Cohen SM. Connecting proliferation 
and apoptosis in development and disease. Nat 
tended transcriptional network for pluripotency of 
embryonic stem cells. Cell. 2006;132(6):1049-
1061.
IFNalpha activates dormant hematopoietic stem 
50. Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI,
Kung AL. Systematic in vivo structure-function 
114(23):4804-4812.
51. Jing X, Zhao DM, Waldschmidt TJ, Xue HH.
GABPbeta2 is dispensable for normal lymphocyte 
development but moderately affects B cell re-
sponses. J Biol Chem. 2008;283(36):24326-
24333.
52. Xue HH, Jing X, Bollenbacher-Reilley J, et al. 
Targeting the GA binding protein beta1L isoform 
does not perturb lymphocyte development and 
dation of the ELK1 target gene network reveals a 
role in the coordinate regulation of core compo-
nants of the gene regulation machinery. Genome 
54. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. 
Genome-wide analyses reveal properties of redund-
ant and specific promoter occupancy within the 
ETS gene family. Genes Dev. 2007;21(15):1882-
1894.
GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells

Shuyang Yu, Kairong Cui, Raja Jothi, Dong-Mei Zhao, Xuefang Jing, Keji Zhao and Hai-Hui Xue